Variant Angina is Associated with Myocarditis.
cytokines
inflammation
myocarditis
variant angina
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
06
2022
accepted:
20
08
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
6
9
2022
Statut:
epublish
Résumé
Vasospastic angina (VSA) is caused by severe diffuse or segmental coronary artery spasms. Patients with variant angina have poor clinical outcomes, although nitrates and calcium blockers help improve patient symptoms because there is no understanding of the etiology and causal treatment. The present study investigated whether VSA is associated with inflammation of the heart. A total of 109 patients with VSA diagnosed by the presence of recurrent angina pectoris, typical electrocardiography, and coronary angiography were recruited, and 61 normal participants and 61 patients with acute myocardial infarction (AMI) and coronary artery stenosis were recruited as controls. The plasma levels of 24 cytokines were measured using a magnetic Luminex assay, and endothelin-1 and histamine levels tested using enzyme-linked immunosorbent assay and mass-spectrometry, respectively, for all participants. Furthermore, four patients with VSA underwent 18-fluorine fluorodeoxyglucose ( The plasma levels of interleukin (IL)-12p70, IL-13, PDL-1, IL-10, IL-6, IL-15, macrophage inflammatory protein (MIP)-1α, and MIP-1β in patients with VSA were significantly higher than those in both normal controls and patients with AMI (p<0.001) but did not differ between normal controls and patients with AMI. Our findings demonstrate that VSA patients have significantly elevated plasma cytokine levels and myocardial and pericoronary inflammation, suggesting that VSA is associated with myocarditis. This study provides novel insights into the etiology and treatment of VSA.
Sections du résumé
Background
UNASSIGNED
Vasospastic angina (VSA) is caused by severe diffuse or segmental coronary artery spasms. Patients with variant angina have poor clinical outcomes, although nitrates and calcium blockers help improve patient symptoms because there is no understanding of the etiology and causal treatment. The present study investigated whether VSA is associated with inflammation of the heart.
Patients and Methods
UNASSIGNED
A total of 109 patients with VSA diagnosed by the presence of recurrent angina pectoris, typical electrocardiography, and coronary angiography were recruited, and 61 normal participants and 61 patients with acute myocardial infarction (AMI) and coronary artery stenosis were recruited as controls. The plasma levels of 24 cytokines were measured using a magnetic Luminex assay, and endothelin-1 and histamine levels tested using enzyme-linked immunosorbent assay and mass-spectrometry, respectively, for all participants. Furthermore, four patients with VSA underwent 18-fluorine fluorodeoxyglucose (
Results
UNASSIGNED
The plasma levels of interleukin (IL)-12p70, IL-13, PDL-1, IL-10, IL-6, IL-15, macrophage inflammatory protein (MIP)-1α, and MIP-1β in patients with VSA were significantly higher than those in both normal controls and patients with AMI (p<0.001) but did not differ between normal controls and patients with AMI.
Conclusion
UNASSIGNED
Our findings demonstrate that VSA patients have significantly elevated plasma cytokine levels and myocardial and pericoronary inflammation, suggesting that VSA is associated with myocarditis. This study provides novel insights into the etiology and treatment of VSA.
Identifiants
pubmed: 36060213
doi: 10.2147/JIR.S378152
pii: 378152
pmc: PMC9439647
doi:
Types de publication
Case Reports
Clinical Trial
Langues
eng
Pagination
4939-4949Informations de copyright
© 2022 Xu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Ann Rheum Dis. 2018 Jan;77(1):70-77
pubmed: 28928271
Can J Cardiol. 2011 Sep-Oct;27(5):601-5
pubmed: 21705187
Eur Heart J. 2020 Oct 1;41(37):3590
pubmed: 32385512
Nat Protoc. 2012 Apr 12;7(5):872-81
pubmed: 22498707
N Engl J Med. 1985 Oct 31;313(18):1138-41
pubmed: 2413358
Int J Cardiol. 2006 Jun 7;110(1):7-14
pubmed: 16249041
Int J Cardiol. 2016 Nov 15;223:791-796
pubmed: 27573612
Sci Rep. 2019 Nov 28;9(1):17783
pubmed: 31780809
J Pharmacol Sci. 2007 Jun;104(2):109-15
pubmed: 17538233
Scand J Rheumatol Suppl. 1987;66:19-25
pubmed: 3502509
Drugs. 1991 Jul;42(1):9-29
pubmed: 1718687
Oxid Med Cell Longev. 2022 Jan 19;2022:9964689
pubmed: 35096275
J Clin Invest. 1996 Feb 1;97(3):769-76
pubmed: 8609234
JACC Case Rep. 2021 Feb 10;3(4):555-560
pubmed: 34317580
Yonsei Med J. 2013 Nov;54(6):1299-304
pubmed: 24142631
J Am Coll Cardiol. 1985 Aug;6(2):321-7
pubmed: 3894473
J Clin Invest. 1986 Jun;77(6):2027-33
pubmed: 2872233
Eur Heart J. 2018 Mar 14;39(11):952-959
pubmed: 29165549
Am J Med. 1959 Sep;27:375-88
pubmed: 14434946
Am Heart J. 1998 Sep;136(3):389-97
pubmed: 9736128
Circulation. 1991 Feb;83(2):476-83
pubmed: 1825037
Free Radic Biol Med. 2018 May 20;120:266-276
pubmed: 29609021
J Am Coll Cardiol. 2018 Jan 30;71(4):414-425
pubmed: 29389358
J Med Life. 2021 Nov-Dec;14(6):853-861
pubmed: 35126758
Transl Res. 2021 May;231:64-75
pubmed: 33232803